406 related articles for article (PubMed ID: 30718277)
21. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.
Yoon JH; Jung SM; Park SH; Kato M; Yamashita T; Lee IK; Sudo K; Nakae S; Han JS; Kim OH; Oh BC; Sumida T; Kuroda M; Ju JH; Jung KC; Park SH; Kim DK; Mamura M
EMBO Mol Med; 2013 Nov; 5(11):1720-39. PubMed ID: 24127404
[TBL] [Abstract][Full Text] [Related]
22. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function.
Zhang Y; Musci T; Derynck R
Curr Biol; 1997 Apr; 7(4):270-6. PubMed ID: 9094310
[TBL] [Abstract][Full Text] [Related]
23. MiRNA-34a reversed TGF-β-induced epithelial-mesenchymal transition via suppression of SMAD4 in NPC cells.
Huang G; Du MY; Zhu H; Zhang N; Lu ZW; Qian LX; Zhang W; Tian X; He X; Yin L
Biomed Pharmacother; 2018 Oct; 106():217-224. PubMed ID: 29960168
[TBL] [Abstract][Full Text] [Related]
24. TGF-β1 inhibits the growth and metastasis of tongue squamous carcinoma cells through Smad4.
Wang X; Sun W; Zhang C; Ji G; Ge Y; Xu Y; Zhao Y
Gene; 2011 Oct; 485(2):160-6. PubMed ID: 21726607
[TBL] [Abstract][Full Text] [Related]
25. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.
Torbenson M; Marinopoulos S; Dang DT; Choti M; Ashfaq R; Maitra A; Boitnott J; Wilentz RE
Hum Pathol; 2002 Sep; 33(9):871-6. PubMed ID: 12378510
[TBL] [Abstract][Full Text] [Related]
26. Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer.
Ai X; Wu Y; Zhang W; Zhang Z; Jin G; Zhao J; Yu J; Lin Y; Zhang W; Liang H; Datta PK; Zhang M; Zhang B; Chen X
Cancer Biol Ther; 2013 Nov; 14(11):1059-67. PubMed ID: 24025354
[TBL] [Abstract][Full Text] [Related]
27. Verteporfin inhibits TGF-β signaling by disrupting the Smad2/3-Smad4 interaction.
Nong J; Shen S; Hong F; Xiao F; Meng L; Li P; Lei X; Chen YG
Mol Biol Cell; 2024 Jul; 35(7):ar95. PubMed ID: 38696259
[TBL] [Abstract][Full Text] [Related]
28. Effects of RNAi-mediated Smad4 silencing on growth and apoptosis of human rhabdomyosarcoma cells.
Ye L; Zhang H; Zhang L; Yang G; Ke Q; Guo H; Bu H
Int J Oncol; 2006 Nov; 29(5):1149-57. PubMed ID: 17016646
[TBL] [Abstract][Full Text] [Related]
29. IFITM3 promotes bone metastasis of prostate cancer cells by mediating activation of the TGF-β signaling pathway.
Liu X; Chen L; Fan Y; Hong Y; Yang X; Li Y; Lu J; Lv J; Pan X; Qu F; Cui X; Gao Y; Xu D
Cell Death Dis; 2019 Jul; 10(7):517. PubMed ID: 31273201
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor-β/SMAD Target gene SKIL is negatively regulated by the transcriptional cofactor complex SNON-SMAD4.
Tecalco-Cruz AC; Sosa-Garrocho M; Vázquez-Victorio G; Ortiz-García L; Domínguez-Hüttinger E; Macías-Silva M
J Biol Chem; 2012 Aug; 287(32):26764-76. PubMed ID: 22674574
[TBL] [Abstract][Full Text] [Related]
31. Smad pathway-specific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1).
Pardali K; Kowanetz M; Heldin CH; Moustakas A
J Cell Physiol; 2005 Jul; 204(1):260-72. PubMed ID: 15690394
[TBL] [Abstract][Full Text] [Related]
32. PEG10 counteracts signaling pathways of TGF-β and BMP to regulate growth, motility and invasion of SW1353 chondrosarcoma cells.
Yahiro Y; Maeda S; Shinohara N; Jokoji G; Sakuma D; Setoguchi T; Ishidou Y; Nagano S; Komiya S; Taniguchi N
J Bone Miner Metab; 2019 May; 37(3):441-454. PubMed ID: 30094509
[TBL] [Abstract][Full Text] [Related]
33. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
Deckers M; van Dinther M; Buijs J; Que I; Löwik C; van der Pluijm G; ten Dijke P
Cancer Res; 2006 Feb; 66(4):2202-9. PubMed ID: 16489022
[TBL] [Abstract][Full Text] [Related]
34. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
[TBL] [Abstract][Full Text] [Related]
35. Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and -independent signaling activity of transforming growth factor-β (TGF-β).
Lin S; Yu L; Yang J; Liu Z; Karia B; Bishop AJR; Jackson J; Lozano G; Copland JA; Mu X; Sun B; Sun LZ
J Biol Chem; 2011 Dec; 286(51):44023-44034. PubMed ID: 22039050
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
Sun B; Fan Y; Yang A; Liang L; Cao J
J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
[TBL] [Abstract][Full Text] [Related]
37. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
Ji GZ; Wang XH; Miao L; Liu Z; Zhang P; Zhang FM; Yang JB
World J Gastroenterol; 2006 Jan; 12(4):644-8. PubMed ID: 16489684
[TBL] [Abstract][Full Text] [Related]
38. TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling.
Felici A; Wurthner JU; Parks WT; Giam LR; Reiss M; Karpova TS; McNally JG; Roberts AB
EMBO J; 2003 Sep; 22(17):4465-77. PubMed ID: 12941698
[TBL] [Abstract][Full Text] [Related]
39. Expression of TGF-beta related Smad proteins in human epithelial skin tumors.
Lange D; Persson U; Wollina U; ten Dijke P; Castelli E; Heldin CH; Funa K
Int J Oncol; 1999 Jun; 14(6):1049-56. PubMed ID: 10339656
[TBL] [Abstract][Full Text] [Related]
40. Wip1 regulates Smad4 phosphorylation and inhibits TGF-β signaling.
Park DS; Yoon GH; Kim EY; Lee T; Kim K; Lee PC; Chang EJ; Choi SC
EMBO Rep; 2020 May; 21(5):e48693. PubMed ID: 32103600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
